Healthcare / Drug Manufacturers - Specialty & GenericBSE
$123.00
-1.45 (-1.17%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 16%
FCF escenarios
weak_data · normalized FCF $-88.0M · quality 33.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
35/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.2B
P/E
22.9x
↑EV/EBITDA
16.2x
↑ROE
5.4%
↑Gross Margin
26.8%
↓Debt/Equity
1.01
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
-12.8%
FCF CAGR
—
FCF margin
-24.6%
FCF / Net income
-6.36x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.06B · net income $40.9M · FCF $-259.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.06B | $1.06B | $1.13B | $1.57B | $1.60B |
| Net Income | $40.9M | $40.9M | $43.8M | $55.5M | $37.9M |
| EBITDA | $114.7M | $114.7M | $128.1M | $127.0M | $97.4M |
| EPS | — | — | 5.82 | 7.37 | 5.03 |
| Gross Margin | 26.8% | 26.8% | 28.0% | 22.9% | 19.8% |
| Operating Margin | 7.4% | 7.4% | 8.3% | 7.3% | 6.2% |
| Net Margin | 3.9% | 3.9% | 3.9% | 3.5% | 2.4% |
| Balance Sheet | |||||
| Debt/Equity | 1.01 | 1.01 | 1.48 | 1.48 | 1.72 |
| Current Ratio | 1.31 | 1.31 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-259.9M | $-259.9M | $-88.0M | $52.1M | $38.8M |
| Returns | |||||
| ROE | 5.4% | 5.4% | 10.1% | 14.2% | 11.3% |
| Valuation | |||||
| P/E | 22.95 | 22.95 | 16.45 | 14.01 | 16.16 |
| EV/EBITDA | 16.25 | 16.25 | 10.65 | 10.66 | 12.16 |
| P/B | 1.64 | 1.64 | 1.66 | 2.00 | 1.83 |
| Growth & Yield | |||||
| Revenue Growth | -6.7% | -6.7% | -27.7% | -1.8% | — |
| EPS Growth | — | — | -21.0% | 46.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+25.9%
Start / end P/E
n/dx → n/dx
EPS bridge
5.82 → n/d
Residual
+25.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.